Kardigan, Inc. filed its quarterly report on Form 10-Q with the SEC on November 12, 2026, covering the fiscal quarter ended September 30, 2026, disclosing its financial condition and ongoing clinical development activities as a clinical-stage biopharmaceutical company.
Key Highlights
- Share count: As of November 9, 2026, the registrant had 93,597,398 shares of common stock, $0.00001 par value per share, outstanding.
- Filer classification: The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.
- Key product candidates: The filing identifies Danicamtiv for genetic DCM, Ataciguat for moderate CAVS, and Tonlamarsen for post-hospitalization management of ASH as the company's primary programs.
- Active trials: Ongoing studies include the Phase 2b KINSHIP-DCM trial of Danicamtiv, the Phase 2b KATALYST-AV trial, and the KARDINAL-ASH Phase 2 clinical trial, among others.
- Financial condition: According to the filing, the company "has incurred significant financial losses since our inception and anticipates that we will continue to incur significant financial losses for the foreseeable future."
- Capital needs: The filing states the company "will require substantial additional capital in order to finance our operations."
Kardigan's Q3 2026 Disclosure: Clinical Pipeline and Financial Position
Kardigan, Inc. (NASDAQ:KARD), headquartered at 506 Carnegie Center Drive, Suite 201, Princeton, NJ 08540, submitted its Form 10-Q for the quarterly period ended September 30, 2026. The filing describes the company as a clinical-stage biopharmaceutical company with a limited operating history, noting that this "may make it difficult to evaluate our current business and predict our future success and viability," according to the registrant's own disclosure.
The filing identifies three principal product candidates: Danicamtiv, being developed for genetic dilated cardiomyopathy (DCM); Ataciguat, targeting moderate calcific aortic valve stenosis (CAVS); and Tonlamarsen, aimed at post-hospitalization management of acute severe hypertension (ASH). The registrant also references its Prolaio platform and its plans to deploy and develop it further. Active clinical programs listed in the filing include the Phase 2b KINSHIP-DCM trial, the Phase 2b KATALYST-AV trial, the KARDINAL-ASH Phase 2 trial, and an ongoing Phase 3 trial of Danicamtiv, with Phase 3 trials of Ataciguat and Tonlamarsen described as planned "if or when initiated."
On the financial side, the filing reports that as of November 9, 2026, the company had 93,597,398 shares of common stock outstanding. The registrant discloses that it has not elected to use the extended transition period for complying with new or revised financial accounting standards under Section 13(a) of the Exchange Act. The filing contains forward-looking statements regarding clinical timelines, regulatory filings, capital requirements, and cash runway, and the registrant notes that such statements are subject to risks and uncertainties, with outcomes that "may be materially different from those expressed or implied."
What Was Disclosed
Kardigan, Inc. filed its quarterly report covering the period ended September 30, 2026, disclosing its status as a clinical-stage company with three named product candidates, multiple active trials, 93,597,398 shares outstanding, and an acknowledged need for substantial additional capital.



Please wait processing your request...